Skip to main content
. 2020 May 16;34:101571. doi: 10.1016/j.redox.2020.101571

Fig. 1.

Fig. 1

EFHD2 increases resistance of lung cancer cells to cisplatin. A) The correlation between EFHD2 mRNA levels and overall survival of lung cancer patients with chemotherapy was analyzed using the Kaplan-Meier-plotter cancer database. The high versus low expression levels of EFHD2 mRNA were split by the median value. B) Lung tumor cells were treated with 5 μM cisplatin for 24 h, and EFHD2 expression was determined by Western blot assay. S.E., short exposure; L.S., long exposure. β-actin, loading control. C) Lung cancer cells were treated with indicated doses of cisplatin for 24 h, cell survival was determined by MTT assay. D) EFHD2 expression in the control and cisplatin-treated (5 μM for 24 h) H1299 cells was examined by flow cytometry assay. E) EFHD2-OE and the control A549 cells and F) EFHD2-KD and the control H1299 cells were treated with indicated doses of cisplatin for 24 h. Cell viability was determined by MTT assay.